IP Library Granted Patent US 8,163,506
Granted Patent B2
US 8,163,506 · App. 10/561,022 · Granted Apr 24, 2012

Use of toll-like receptor-expressing cells

Assignee: Meiji Co., Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,163,506
App. No.
10/561,022
Granted
Apr 24, 2012
Kind
B2
Abstract

Swine Toll-like receptor 9 (TLR9)-expressing cells are prepared by cloning a TLR9 gene from swine intestinal Peyer's patches. Functional analysis on CpG DNAs using the above cells revealed that swine TLR9 shows a higher recognition ability for a human CpG DNA motif (CpG2006) than for a mouse-specific CpG DNA motif (CpG1826). When the mRNA expression levels in various tissues are compared by the real-time PCR method, it is found out that the mRNA is expressed in Peyer's patches and mesenteric lymph nodes, which play important roles in the intestinal tract immune system, at a level thrice as much as in spleen or more. Thus, the cells expressing an intestinal tract tissue-expressed TLR (for example, TLR9) can be used to identify samples capable of activating the intestinal tract immune system.

Claims (13)

1. A method of screening for a sample that activates the intestinal tract immune system, comprising the steps of:

(a) contacting a test sample with an isolated cell expressing a Toll-like receptor 9 (TLR9) encoded by a DNA comprising the nucleotide sequence shown in SEQ ID NO: 1;

(b) measuring activity of the TLR9 using signal transduction in the cell as an indicator; and

(c) selecting the test sample as a sample that activates the intestinal tract immune system if the activity of the TLR9 is increased as compared to activity of the TLR9 in a cell not contacted with the test sample.

2. A method for producing a pharmaceutical composition that activates the intestinal tract immune system, comprising the steps of claim 1 , and a further step of mixing the sample selected as a sample that activates the intestinal tract immune system with a pharmaceutically acceptable carrier.

3. A method of screening for microorganisms that activate the intestinal tract immune system, comprising the steps of:

(a) preparing an extract from a test microorganism;

(b) contacting the extract with an isolated cell expressing a Toll-like receptor 9 (TLR9) encoded by a DNA comprising the nucleotide sequence shown in SEQ ID NO: 1;

(c) measuring activity of the TLR9 using signal transduction in the cell as an indicator; and

(d) selecting the test microorganism as a microorganism that activates the intestinal tract immune system if the activity of the TLR9 is increased as compared to activity of the TLR9 in a cell not contacted with the extract.

4. A method for producing a food composition that activates the intestinal tract immune system, comprising the steps of claim 3 , and then mixing the microorganism selected in part (d) of claim 3 with a dietarily acceptable carrier.

5. The method of claim 4 , wherein the microorganism is a lactic acid bacterium.

6. The method, according to claim 4 , wherein the dietarily acceptable carrier is a dairy product.

Assignments (2)
CHANGE OF NAME Recorded Nov 17, 2011
From: MEIJI DAIRIES CORPORATION
To: MEIJI CO., LTD.
Reel/Frame 027244/0433 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 24, 2007
From: SAITO, TADAO; SHIMOSATO, TAKESHI; KITAZAWA, HARUKI
To: MEIJI DAIRIES CORPORATION
Reel/Frame 019340/0175 →
Priority Claims (1)
JP 2003-172132 · Jun 17, 2003 · national
Continuity (1)
Related Publication 20070298449A1 · Dec 27, 2007